![Photograph of the High Court of Australia, symbolising the landmark ruling in Self Care v Allergan [2023] HCA 8, which clarified trade mark use and misleading conduct under Australian law, featured by Pentana Stanton Lawyers.](https://0b442dd2.delivery.rocketcdn.me/wp-content/uploads/2025/06/ChatGPT-Image-Jun-20-2025-02_16_58-PM-683x1024.webp)
Key Takeaways
- The High Court found that the phrase “instant Botox® alternative” was used descriptively rather than as a trade mark. It did not function as a badge of origin and was not used to distinguish goods under the Trade Marks Act 1995 (Cth).
- The Court clarified that a trade mark’s commercial reputation (e.g., BOTOX) is not relevant when assessing deceptive similarity under section 120(1). The focus must be on how the marks appear on the Register—not how well-known the product is.
- The High Court ruled that the name PROTOX was not deceptively similar to BOTOX, reversing the Full Court’s finding and reaffirming that consumer confusion must be based on the mark itself, not market context or fame.
- The Court found that Self Care’s advertising, including the phrase “instant Botox® alternative”, did not mislead or deceive consumers under the ACL. The context, packaging, and explanatory wording made the limited effect duration clear.
- This decision provides strong guidance for businesses, confirming that responsible comparative marketing and descriptive phrases are lawful when properly contextualised and do not mislead consumers or infringe trade mark rights.
High Court Clarifies Trade Mark Use and Misleading Conduct: Self Care IP Holdings Pty Ltd & Anor v Allergan Australia Pty Ltd & Anor [2023] HCA 8
Background and Context
The High Court of Australia’s decision in Self Care IP Holdings Pty Ltd & Anor v Allergan Australia Pty Ltd & Anor [2023] HCA 8 is a landmark ruling that addresses the boundaries of trade mark infringement and misleading conduct in the context of comparative advertising and product branding. The dispute centred on Self Care’s marketing of topical skincare products as an “instant Botox® alternative” and under the brand name “PROTOX”, and whether these uses infringed Allergan’s well-known BOTOX trade mark or breached the Australian Consumer Law (ACL) by misleading consumers.
Allergan, the manufacturer of the injectable pharmaceutical Botox, holds registered trade marks for BOTOX in both Class 5 (pharmaceuticals) and Class 3 (cosmetic creams), the latter being a defensive registration. Self Care, meanwhile, marketed its FREEZEFRAME range, including the topical cream Inhibox (promoted as an “instant Botox® alternative”) and a separate product named PROTOX.
Litigation History
- Federal Court (Primary Judge): The primary judge found in favour of Self Care, holding that “instant Botox® alternative” was used descriptively and not as a trade mark, and that PROTOX was not deceptively similar to BOTOX. The judge also found no misleading or deceptive conduct under the ACL.
- Full Court of the Federal Court: On appeal, the Full Court reversed the decision, finding that PROTOX was deceptively similar to BOTOX, that “instant Botox® alternative” was used as a trade mark and infringed BOTOX, and that the phrase conveyed a misleading representation regarding long-term efficacy.
- High Court: Self Care appealed to the High Court, which was asked to consider whether the phrases and marks in question constituted trade mark use, whether they were deceptively similar, the relevance of BOTOX’s reputation, and whether the advertising was misleading under the ACL.
Key Legal Issues and High Court Findings
1. Use as a Trade Mark
The High Court unanimously held that the phrase “instant Botox® alternative” was used descriptively and not as a trade mark. The Court emphasised that for a phrase to be considered a trade mark, it must function as a “badge of origin” distinguishing the goods of one trader from those of another. In this case, the phrase was presented inconsistently and always in a secondary position to the dominant FREEZEFRAME and INHIBOX branding. The Court described the phrase as “adspeak” rather than a badge of origin, and thus not trade mark use within the meaning of the Trade Marks Act 1995 (Cth).
2. Deceptive Similarity
The High Court rejected the Full Court’s finding that PROTOX was deceptively similar to BOTOX. The test for deceptive similarity centres on the notional buyer’s imperfect recollection of the registered mark. The Court clarified that the reputation of the registered trade mark (in this case, BOTOX) is irrelevant to the assessment of deceptive similarity under section 120(1) of the Trade Marks Act. The focus must remain on the marks themselves as they appear on the Register, not on their commercial reputation or fame.
3. Misleading or Deceptive Conduct under the ACL
The High Court found that Self Care’s use of the phrase “instant Botox® alternative” did not contravene the ACL. The Court held that the phrase, when considered in the context of the packaging and website, did not convey that Inhibox would have effects of similar duration to Botox injections. The packaging clearly stated that the effects lasted for hours, not for the extended period associated with Botox. The Court applied the test from Campomar Sociedad Limitada v Nike International Ltd, focusing on the perspective of the ordinary or reasonable consumer and the overall context, rather than isolated words.
Legal and Commercial Implications
This decision provides important guidance for businesses on the use of comparative advertising and descriptive phrases. The High Court has clarified that:
- Descriptive or comparative phrases do not amount to trade mark use unless they function as a badge of origin.
- The reputation of a registered trade mark is not relevant when assessing deceptive similarity for infringement purposes.
- The context and presentation of marketing claims are critical in determining whether conduct is misleading under the ACL.
The ruling enhances certainty for businesses engaging in competitive advertising, confirming that responsible use of comparative language does not inherently infringe trade mark rights or breach consumer law.
Conclusion
The High Court’s decision in Self Care v Allergan [2023] HCA 8 marks a significant clarification of the law regarding trade mark infringement and misleading conduct. It underscores the importance of context, presentation, and the statutory framework in both trade mark and consumer law, providing a clear and structured approach for businesses navigating these issues in the Australian market.
If your business uses comparative marketing or faces trade mark disputes, Pentana Stanton Lawyers offers expert legal guidance in protecting your brand and ensuring compliance with Australian consumer law.
Contact us today to speak with our experienced intellectual property and consumer law specialists.